Refine by
Tissue And Cell Analysis Articles & Analysis
8 news found
Immune System Tissue Microarrays from CD BioSciences are meticulously designed to feature a variety of tissue cores, allowing researchers to simultaneously analyze the expression of multiple immune markers in a variety of tissues and providing invaluable information for understanding the distribution, function and interactions of immune ...
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technology, announced the launch of its new 3D Tissue Imaging Services to researchers with comprehensive solutions for 3D imaging of tissues, including 3D Immunolabeling, Tissue Removal, 3D Imaging, and Quantitative Image Analysis. Traditional ...
Employing an automated system, 3D heart tissues are fabricated with cardiomyocytes derived from human induced pluripotent stem cells. ...
Its PROTAC in vivo evaluation services encompass general studies of toxicology and in vivo pharmacokinetics, tests of allergy and in vitro hemolysis, as well as immunotoxicology analysis. Scientists of BOC Sciences can fully elucidate drug toxicity by evaluating single administration, multiple administrations, dose range exploration, or maximum tolerance within animal models. ...
RSIP Vision, an experienced leader in driving innovation for medical imaging through advanced AI and computer vision solutions, today announces a new tool for Total Shoulder Arthroplasty (TSA) planning. This tool performs segmentation of the shoulder bones from shoulder MRI scan, which is usually performed in shoulder healthcare. The segmentation output undergoes super-resolution enhancement to ...
Hard-to-detect cancers like glioblastoma can have survival rates in the single-digit percentages and require elaborate techniques to detect, treat, and monitor. Reveal Surgical is working on changing that reality through its new, AI-based Sentry technology, which leverages a combination of AI and Raman spectroscopy to provide real-time tissue diagnostics during surgery for otherwise-invisible ...
SAN DIEGO, November 22, 2019 – Avelas Biosciences, Inc., a clinical-stage oncology company developing AVB-620 for real-time cancer detection is pleased to announced the addition of Susan Stimson as a Director of the company. “Susan brings an exceptional background and skillset to the Avelas Board. She has had incredible success throughout her career and her knowledge and experiences ...
The poster, titled “Use of a fluorescent activatable cell penetrating peptide imaging agent (AVB-620) to identify positive and close margins intraoperatively,” is available at the conference’s poster session and online after the conference. ...